Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CD44 | P16070 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2669824 | 0.86 | CD44 (0.44) | ALDH1A1TSHRGAAMAPTKDM4E | |
| SCHEMBL22922896 | 0.86 | ALDH1A1 (0.52) | ALDH1A1TSHRGAAMAPTKDM4E | |
| SCHEMBL4027643 | 0.82 | ALDH1A1 (0.48) | ALDH1A1TSHRGAAMAPTKDM4E | |
| SCHEMBL1494527 | 0.82 | ALDH1A1 (0.38) | ALDH1A1TSHRGAAMAPTKDM4E | |
| SCHEMBL17736226 | 0.78 | ALDH1A1 (0.52) | ALDH1A1TSHRGAAMAPTCYP3A4 | |
| SCHEMBL9610077 | 0.77 | SMN1; SMN2 (0.39) | ALDH1A1TSHRGAAMAPTKDM4E | |
| SCHEMBL5525333 | 0.75 | CD44 (0.43) | ALDH1A1TSHRGAAMAPTCYP3A4 | |
| SCHEMBL11682705 | 0.75 | CYP3A4 (0.66) | ALDH1A1GAAMAPTKDM4ELMNA | |
| SCHEMBL5505433 | 0.75 | CD44 (0.44) | ALDH1A1TSHRGAAMAPTKDM4E | |
| SCHEMBL29434817 | 0.75 | ALDH1A1 (0.46) | ALDH1A1TSHRGAAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760762-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11345653-B2 | Compositions and methods for reactivating cholinesterases | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20190345097-A1 | Compositions and Methods for Reactivating Cholinesterases | The Henry M. Jackson Foundation for the Advancemen t of Military Medicine, Inc. (US) | 2019-11-14 | — | — | US | disclosed |
| EP-3472127-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING CHOLINESTERASES | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017218886-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING CHOLINESTERASES | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| EP-1968635-B1 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX INC (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20100093880-A1 | RECYCLING CLEAVAGE OF POLYURETHANES | PUREC GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| EP-0450179-A1 | Polyurethane ureas having diaminoanthraquinones as chain extending agents and process for the preparation of the polyurethane ureas | BAYER AG (DE) | 1991-10-09 | — | — | EP | disclosed |
| US-4281151-A | ANTIALLERGENS, ANTIANAPHYLACTIC AGENTS | THE UPJOHN COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
| US-4186127-A | ANTIALLERGENS | THE UPJOHN COMPANY (US) | 1980-01-29 | — | — | US | disclosed |
| US-4165319-A | Isoindoline pigments | CIBA-GEIGY CORPORATION (US) | 1979-08-21 | — | — | US | disclosed |
| US-4159278-A | PROPHYAXIS, ANTIALLERGENS, SENSITIZATION | THE UPJOHN COMPANY (US) | 1979-06-26 | — | — | US | disclosed |
| US-4152510-A | AROMATIC DIAMINE CHAIN EXTENDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1979-05-01 | — | — | US | disclosed |
| US-4126617-A | PROPHYLAXIS | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-4095028-A | PROPHYLAXIS, ALLERGIES | THE UPJOHN COMPANY (US) | 1978-06-13 | — | — | US | disclosed |
| US-4089973-A | Cyano phenylene dioxamic acid compounds used in the treatment of allergy | THE UPJOHN COMPANY (US) | 1978-05-16 | — | — | US | disclosed |
| US-3993679-A | ANTIALLERGY | THE UPJOHN COMPANY (US) | 1976-11-23 | — | — | US | disclosed |
| US-3959289-A | PROPHYLACTICS IN ALLERGIES | THE UPJOHN COMPANY (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760762-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | CDK1, CDKN1A, CDKL1 | ALDH1A1 3077/4885TSHR 2452/4885GAA 4060/4885 |
| US-11345653-B2 | Compositions and methods for reactivating cholinesterases | ACHE, BCHE, CHAT | ALDH1A1 735/4885TSHR 3268/4885GAA 456/4885 |
| US-20190345097-A1 | Compositions and Methods for Reactivating Cholinesterases | ACHE, BCHE, CHAT | ALDH1A1 735/4885TSHR 3268/4885GAA 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.